中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2013年
3期
10-13
,共4页
卵巢肿瘤%化学疗法,肿瘤,局部灌注%重组人血管内皮抑制素
卵巢腫瘤%化學療法,腫瘤,跼部灌註%重組人血管內皮抑製素
란소종류%화학요법,종류,국부관주%중조인혈관내피억제소
Ovarian neoplasms%Chemotherapy,cancer,regional perfusion%Recombinant human endostatin
目的 观察重组人血管内皮抑制素(恩度)联合静脉化疗和腹腔热灌注化疗治疗晚期卵巢癌的临床疗效.方法 将61例晚期卵巢癌患者按照随机数字表法分为治疗组(31例)和对照组(30例),治疗组给予恩度+TP方案(紫杉醇静脉化疗+顺铂腹腔热灌注化疗)；对照组给予恩度+TP方案(紫杉醇静脉化疗+顺铂静脉化疗).观察两组患者的复发率、生存率、生活质量改善情况及不良反应.结果 治疗组患者中64.5％(20/31)的生活质量得到改善,显著高于对照组的33.3％(10/30)(x2=5.931,P=0.015).治疗组患者的1、2年复发率显著低于对照组[17.2％(5/29)比41.4％(12/29)和34.5％(10/29)比62.1％(18/29),P=0.043、0.036].治疗组患者的1、2年生存率显著高于对照组[93.1％(27/29)比72.4％(21/29)和79.3％(23/29)比51.7％(15/29),P=0.037、0.027].治疗组患者恶心、呕吐的发生率为67.7％(21/31),对照组为93.3％(28/30),两组比较差异有统计学意义(P=0.012).两组患者骨髓抑制、脱发及肝肾功能损害等的发生率比较差异无统计学意义(P＞0.05).结论 恩度联合静脉化疗和腹腔热灌注化疗治疗晚期卵巢癌安全、有效,可以提高患者的生活质量,降低复发率,延长生存期.
目的 觀察重組人血管內皮抑製素(恩度)聯閤靜脈化療和腹腔熱灌註化療治療晚期卵巢癌的臨床療效.方法 將61例晚期卵巢癌患者按照隨機數字錶法分為治療組(31例)和對照組(30例),治療組給予恩度+TP方案(紫杉醇靜脈化療+順鉑腹腔熱灌註化療)；對照組給予恩度+TP方案(紫杉醇靜脈化療+順鉑靜脈化療).觀察兩組患者的複髮率、生存率、生活質量改善情況及不良反應.結果 治療組患者中64.5％(20/31)的生活質量得到改善,顯著高于對照組的33.3％(10/30)(x2=5.931,P=0.015).治療組患者的1、2年複髮率顯著低于對照組[17.2％(5/29)比41.4％(12/29)和34.5％(10/29)比62.1％(18/29),P=0.043、0.036].治療組患者的1、2年生存率顯著高于對照組[93.1％(27/29)比72.4％(21/29)和79.3％(23/29)比51.7％(15/29),P=0.037、0.027].治療組患者噁心、嘔吐的髮生率為67.7％(21/31),對照組為93.3％(28/30),兩組比較差異有統計學意義(P=0.012).兩組患者骨髓抑製、脫髮及肝腎功能損害等的髮生率比較差異無統計學意義(P＞0.05).結論 恩度聯閤靜脈化療和腹腔熱灌註化療治療晚期卵巢癌安全、有效,可以提高患者的生活質量,降低複髮率,延長生存期.
목적 관찰중조인혈관내피억제소(은도)연합정맥화료화복강열관주화료치료만기란소암적림상료효.방법 장61례만기란소암환자안조수궤수자표법분위치료조(31례)화대조조(30례),치료조급여은도+TP방안(자삼순정맥화료+순박복강열관주화료)；대조조급여은도+TP방안(자삼순정맥화료+순박정맥화료).관찰량조환자적복발솔、생존솔、생활질량개선정황급불량반응.결과 치료조환자중64.5％(20/31)적생활질량득도개선,현저고우대조조적33.3％(10/30)(x2=5.931,P=0.015).치료조환자적1、2년복발솔현저저우대조조[17.2％(5/29)비41.4％(12/29)화34.5％(10/29)비62.1％(18/29),P=0.043、0.036].치료조환자적1、2년생존솔현저고우대조조[93.1％(27/29)비72.4％(21/29)화79.3％(23/29)비51.7％(15/29),P=0.037、0.027].치료조환자악심、구토적발생솔위67.7％(21/31),대조조위93.3％(28/30),량조비교차이유통계학의의(P=0.012).량조환자골수억제、탈발급간신공능손해등적발생솔비교차이무통계학의의(P＞0.05).결론 은도연합정맥화료화복강열관주화료치료만기란소암안전、유효,가이제고환자적생활질량,강저복발솔,연장생존기.
Objective To observe the clinical efficacy of recombinant human endostatin (endostar)combined with intravenous chemotherapy and intraperitoneal hyperthermic perfusion chemotherapy for advanced ovarian cancer (AOC).Methods Sixty-one patients with AOC were divided into treatment group (31 cases) and control group (30 cases) by table of random digit.The treatment group was given endostar +TP project (paclitaxel intravenous chemotherapy + cisplatin intraperitoneal hyperthermic perfusion chemotherapy).The control group was given endostar + TP project (paclitaxel and cisplatin intravenous chemotherapy).The recurrence rate,survival rate,improvement of quality of life (QOL) and drug side effects were observed in two groups.Results The improvement rate of QOL in treatment group was significantly higher than that in control group [64.5％(20/31) vs.33.3％(10/30),x2 =5.931,P=0.015].The 1-year and 2-year recurrence rate in treatment group were significantly lower than those in control group [17.2％(5/29)vs.41.4％(12/29),34.5％(10/29) vs.62.1％(18/29),P=0.043 and 0.036].The 1-year and 2-year survival rate in treatment group were significantly higher than those in control group [93.1％(27/29) vs.72.4％(21/29),79.3％ (23/29) vs.51.7％ (15/29),P =0.037 and 0.027].The incidence of nausea and vomiting in treatment group was significantly lower than that in control group [67.7％ (21/31) vs.93.3％ (28/30),P =0.012],there was no significant differences in bone marrow suppression,hair loss and liver and renal injury incidence between two groups (P ＞0.05).Conclusion Endostar combined with intravenous chemotherapy and intraperitoneal hyperthermic perfusion chemotherapy for AOC is safe and effective,and can improve patients' QOL,reduce the rate of recurrence and prolong survival time.
